Alzheimer's Assocation Research only
All of
  • Go to
  • Research Center
  • AAIC
  • Journal
  • Grants
  • TrialMatch
  • Press
  • Donate
  • Contact Us
Science and Progress
Clinical Trials
Funding and Collaboration
You can Help
Stay Current
Video and Resources

Text Size

Small text Medium text Large text

Research Grants 2005

To view an abstract, select an author from the vertical list on the left side.

2005 Grant - Zhao

Estrogen Receptor Subtype-Selective Phytoestrogens for Prevention of Alzheimer's Disease

Liqin Zhao, Ph.D.
University of Southern California
Los Angeles, California

2005 New Investigator Research Grant

Phytoestrogens are naturally occurring plant chemicals which can mimic some of the actions of the hormone estrogen. Because there are indications that estrogen can protect nerve cells, there is considerable interest in phytoestro-gens as potential drugs for treating Alzheimer's and other neurodegenerative diseases.

Liqin Zhao, Ph.D., and colleagues plan to investigate which phytoestrogens, or combination of phytoestrogens, may provide the best therapeutic benefit. One factor that needs to be considered is the affinity of the phytoestrogens towards receptors, or "docking sites" on the surface of cells. There are two estrogen receptors, alpha and beta, in the human brain. Evidence suggests
that estrogen can only have a neuroprotective effect when it binds to alpha receptors.

Zhao and colleagues hypothesize that phytoestrogens that selectively bind to alpha receptors might be a better drug than one that binds equally well to both alpha and beta receptors. The also posit that a combination of phytoestrogens might prove more effective than a single molecule.

To test these theories, the scientists plan to search for phytoestrogens from a pool of natural molecules and test their ability to protect neurons. In studies with animals, they will also determine whether these molecules will be able to penetrate the brain's defenses and how they might affect the uterus and breast, organs that are extremely sensitive to the action of estrogens. Outcomes of this work may demonstrate the utility of developing estrogen-like therapies for Alzheimer's disease.

Alzheimer's Association International Conference | July 16-20, 2017, London, England

Abstract Submissions Now Open

The Scientific Program Committee is now accepting submissions for poster
presentations, oral presentations and featured research sessions.